HIF-2α-IN-13, identified by its CAS number 3034488-42-8, is a small molecule inhibitor that targets the hypoxia-inducible factor 2 alpha (HIF-2α), a transcription factor involved in cellular responses to low oxygen levels. This compound is of particular interest in cancer research, as HIF-2α plays a crucial role in tumor growth and metastasis under hypoxic conditions. The characteristics of HIF-2α-IN-13 include its potential to disrupt the interaction between HIF-2α and its coactivators, thereby inhibiting the transcription of genes that promote angiogenesis and tumor survival. The compound is typically characterized by its molecular structure, which includes specific functional groups that confer its biological activity. Additionally, HIF-2α-IN-13 has been studied for its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), which are essential for evaluating its therapeutic potential and safety profile in clinical settings. Overall, HIF-2α-IN-13 represents a promising avenue for targeted cancer therapy, particularly in tumors that exhibit HIF-2α overexpression.

HIF-2α-IN-13

3034488-42-8: HIF-2α-IN-13, identified by its CAS number 3034488-42-8, is a small molecule inhibitor that targets the hypoxia-inducible factor 2 alpha (HIF-2α), a transcription factor involved in cellular responses to low oxygen levels. This compound is of particular interest in cancer research, as HIF-2α plays a crucial role in tumor growth and metastasis under hypoxic conditions. The characteristics of HIF-2α-IN-13 include its potential to disrupt the interaction between HIF-2α and its coactivators, thereby inhibiting the transcription of genes that promote angiogenesis and tumor survival. The compound is typically characterized by its molecular structure, which includes specific functional groups that confer its biological activity. Additionally, HIF-2α-IN-13 has been studied for its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), which are essential for evaluating its therapeutic potential and safety profile in clinical settings. Overall, HIF-2α-IN-13 represents a promising avenue for targeted cancer therapy, particularly in tumors that exhibit HIF-2α overexpression.

HIF-2α-IN-13 (18) acts as a HIF-2α inhibitor and exhibits an IC 50 value of 2.7 μM.

CAS 3034488-42-8

HIF-2α-IN-13

HIF-2α-IN-13

Ref: TM-T88052